|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Keith_Dionne
|
|
gptkbp:developedBy
|
therapies for neurodegenerative diseases
therapies for rare diseases
|
|
gptkbp:focusesOn
|
autophagy-based therapeutics
|
|
gptkbp:foundedIn
|
2018
|
|
gptkbp:founder
|
gptkb:James_E._Rothman
gptkb:Stéphane_Bancel
gptkb:Andrea_Ballabio
gptkb:Beth_Levine
gptkb:Rosana_Kapeller
gptkb:Bruce_Booth
|
|
gptkbp:headquartersLocation
|
gptkb:Cambridge,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Casma Therapeutics
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:investor
|
gptkb:Lightstone_Ventures
gptkb:Eli_Lilly_and_Company
gptkb:Casdin_Capital
gptkb:Third_Rock_Ventures
gptkb:Mission_BioCapital
gptkb:The_Column_Group
gptkb:Astellas_Venture_Management
gptkb:Eventide_Asset_Management
gptkb:Eventide_Fund
gptkb:Amgen_Ventures
|
|
gptkbp:numberOfEmployees
|
gptkb:James_E._Rothman
gptkb:Beth_Levine
gptkb:Rosana_Kapeller
gptkb:Keith_Dionne
|
|
gptkbp:specializesIn
|
autophagy modulation
|
|
gptkbp:website
|
https://www.casmatx.com/
|
|
gptkbp:bfsParent
|
gptkb:Mark_Leschly
|
|
gptkbp:bfsLayer
|
6
|